Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-01-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2023-004金陵药业股份有限公司关于2023年度日常关联交易预计情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the expected daily related party transactions for the year 2023. It includes details about the nature, amounts, and counterparties of these related party transactions, as well as independent directors' opinions and board meeting resolutions. The document is a formal disclosure of anticipated related party transactions requiring shareholder approval, consistent with regulatory requirements for listed companies. It does not contain financial statements or comprehensive financial performance data, nor is it a transcript, audit report, or capital update. It is a regulatory announcement about related party transactions expected in the upcoming fiscal year, which fits best under the category of Regulatory Filings (RNS). The document length (5412 characters) and content confirm it is not merely a brief notice or report publication announcement but a substantive regulatory disclosure.
2023-01-18 Chinese
金陵药业股份有限公司关于收到部分拆迁补偿款的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the receipt of partial demolition compensation payments. It details the amounts received, references prior announcements, and discusses the expected accounting impact on net profit. The document is short (1176 characters) and serves as an update on a specific financial event rather than a comprehensive financial report or audit. It does not contain full financial statements or detailed financial analysis. It is not a report publication announcement since it provides substantive new information about received payments and their impact. The content fits best under Capital/Financing Update (CAP) as it relates to receipt of funds and financial impact from a capital event (demolition compensation).
2023-01-03 Chinese
金陵药业股份有限公司第八届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 25th meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting results, and decisions made, specifically about granting restricted stock to incentive recipients. It includes references to compliance with laws and company articles, and mentions related announcements published elsewhere. The document is a formal disclosure of board decisions rather than a full management report or financial statement. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2022-12-28 Chinese
金陵药业监事会关于公司向激励对象授予预留限制性股票核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion regarding the granting of reserved restricted shares to incentive recipients under a 2021 restricted stock incentive plan. It references compliance with company law, securities law, and stock incentive management measures. The content focuses on the approval and verification of stock incentive grants rather than financial results, management changes, or regulatory filings. It is not an annual report, earnings release, or management report. It is also not a proxy solicitation or voting result announcement. The document is a formal opinion related to stock incentive grants, which fits best under Regulatory Filings (RNS) as it is a compliance and verification statement rather than a financial report or announcement of a capital change (which would be SHA). The document length is short and it is a formal opinion, not a report publication announcement or certification letter. Therefore, the best classification is Regulatory Filings (RNS).
2022-12-28 Chinese
金陵药业股份有限公司关于向激励对象授予预留限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of reserved restricted shares (restricted stock units) to incentive recipients by Jinling Pharmaceutical Co., Ltd. It includes specifics about the number of shares, grant price, conditions, approval procedures, legal and financial advisor opinions, and the impact on the company's financials. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a formal announcement about a capital/financing activity related to share-based compensation and equity incentives. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-12-28 Chinese
金陵药业2021年限制性股票激励计划预留授予激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is a list of reserved restricted stock incentive plan recipients for Jinling Pharmaceutical Co., Ltd. It details the allocation of restricted stock to executives and key personnel, including quantities and percentages of total shares. This type of document relates to share-based compensation and equity incentive plans, which typically fall under announcements related to share issues or capital changes. The document is short (1000 characters) and does not contain financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a management change announcement or a voting result. The content is about stock incentives, which aligns best with Share Issue/Capital Change filings.
2022-12-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.